Tom Powles/bartscancer.london
Aug 18, 2025, 13:03
Tom Powles Shared Positive Results from IMVIGOR011 Bladder Cancer Trial
Tom Powles, Head of Solid Tumor Research at Barts Cancer Institute, shared a post on X:
“IMVIGOR011: Atezo vs placebo in ctDNA+ve bladder ca (including -ve becoming +ve) post cystectomy hit OS/PFS. It also tracks outcomes in the ctDNA-ve, supporting a ctDNA adjusted approach. It’s been a long journey for atezo in UC but it has +ve OS at last.”
More posts featuring Tom Powles on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 8, 2025, 08:22
Sep 8, 2025, 08:21
Sep 8, 2025, 08:19
Sep 8, 2025, 08:15
Sep 8, 2025, 08:13
Sep 8, 2025, 08:02
Sep 8, 2025, 07:51